Lundbeck

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partners.